CEO of Raygent Associates
Contributor's Links: Raygent

Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 35 years executive experience including Abbott and JNJ and has been involved three successful start-ups. Before starting Raygent and other companies he was also a ... more


Biotech Stocks Are Lagging, Is It Time To Rebalance Your Healthcare Portfolio?
You may have seen that biotech stocks have been in a funk. The IBB has broken through the SMA-200 support line near $160 and it holds a perilous perch at $155, up only about 2.5% year-to-date. The IBB has been down over 10% for the past 30 days.
Biotech Playbook Revisited As Technicals Weaken
Recent breakthroughs with mRNA vaccines over the past two years have shown the enormous potential for transformative therapies. DNA sequencing took off five years ago and new applications are still being developed.
Look For The Q4 Biotech Bounce In Mid-Small Caps
Large-cap biopharma stocks are off their highs because of prospects that drug prices may be directly negotiated through Medicare but several Democrats are not in agreement as to how this could be best accomplished.
Small Cap Biotechs Sagging But More Deals Are Likely To Perk Up The Market
Despite record highs in the Nasdaq recently at the 15,000 level the biotech market seems sluggish. Speculation has ebbed. As if we need a green screen every day.
Healthcare Stocks Hit New Highs But Small Caps Lag
Many smaller cap biotech stocks trade on news and milestones and have no earnings so require more expertise in the field.
Large Cap Biopharma Stocks Provide Growth And Value
The S&P 500 Healthcare Index was up 0.53% and biotech still lags in healthcare yet Large Cap Biopharma is doing well YTD.


Latest Comments
Regulatory News For Rare Disease Products - Hot Stocks: BLUE, ICPT, SRPT
6 years ago

Getting trial information and following them is the hard part as it takes too much time. Just sett up the stocks in a Yahoo portfolio and track daily. The WEB site of the Company usually lets you know if trial results are coming in and when.

In this article: BLUE, ICPT, SRPT
Biotech Buzz Is Broken
6 years ago

Here is the YTD for KITE down 4.7%:

In this article: JUNO, KITE, GILD, REGN
2015 Biotech Stock Preview: Rhythms Of The “PermaBull”
6 years ago

prefer a fund like FBIOX but XBI will work when the market heats up

In this article: XLV, FBT, FBIOX, GILD
1 to 3 of 3 comments




Latest Posts
Biotech Investing Strategy For 2020: Part I… Update-1 Jan 24
We remain on hold for taking on new positions. Biotech and healthcare stocks have made nice gains so let’s get through the earnings cycle.
Asco Rally Fizzles: The Nascent Rally In Biotech Stocks Fades
ASCO Rally Fizzles Two Weeks ahead of May 31-June 4 Meeting: XBI down 0.9% to $83.

Work Experience

Raygent Associates
January 1990 - Present (32 years 3 months)
Biotechnology Intelligence


Penn State University
Rutgers University